Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors

被引:0
|
作者
CordonCardo, C
Zhang, ZF
Dalbagni, G
Drobnjak, M
Charytonowicz, E
Hu, SX
Xu, HJ
Reuter, VE
Benedict, WF
机构
[1] MEM SLOAN KETTERING CANC CTR,DEPT EPIDEMIOL & BIOSTAT,NEW YORK,NY 10021
[2] MEM SLOAN KETTERING CANC CTR,DEPT SURG,SERV UROL,NEW YORK,NY 10021
[3] MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030
[4] MD ANDERSON CANC CTR,DEPT MOL ONCOL,HOUSTON,TX 77030
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Altered patterns of p53 and PRE expression have been reported to be frequent events and to have prognostic significance in bladder cancer, To assess the potential adverse consequences of having altered patterns of both p53 and pRB proteins in patients with bladder neoplasms compared with having one or neither abnormality, we have studied a cohort of superficial transitional cell carcinomas of the urinary bladder by immunohistochemical analysis, The present study included 59 well-characterized superficial transitional cell carcinomas (Ta, n = 28; T1, n = 31) for which clinicopathological variables were available, Nuclear overexpression of p53 was identified in 22 cases (37%), A statistically significant association was observed between the p53-positive phenotype and disease progression (P < 0.001), as well as reduced survival (P < 0.001), Undetectable levels of pRB were observed in 11 cases (19%), Patients with a pRB-negative phenotype had a more frequent disease progression (P = 0.014) and decreased overall survival (P = 0.014), We also observed a significant association between altered p53 and undetectable pRB expression patterns (P = 0.001), Nine tumors showed both a p53-positive and a pRB-negative phenotype, There was an even more marked increase in progression (P = 0.00005) and decreased overall survival (P = 0.0004) in patients whose tumors had both alterations after controlling for tumor stage, tumor grade, and suspicion of vascular invasion, These data suggest that alterations of p53 and pRB have a cooperative negative effect on both progression and survival in primary bladder cancer, It may be postulated that aberrant p53 and pRB expression deregulates cell cycle control at the G(1) checkpoint and engenders tumor cells with reduced response to programmed cell death, The imbalance produced by an enhanced proliferative activity and a decreased apoptotic rate may determine the aggressive clinical course of the bladder tumors harboring both p53 and pRB alterations.
引用
收藏
页码:1217 / 1221
页数:5
相关论文
共 50 条
  • [31] Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy
    Jahnson, S
    Karlsson, MG
    JOURNAL OF UROLOGY, 1998, 160 (04): : 1291 - 1296
  • [32] P53 ALTERATIONS IN GASTRIC-CARCINOMA - A STUDY OF 56 PRIMARY TUMORS AND 204 NODAL METASTASES
    SERUCA, R
    DAVID, L
    CASTEDO, S
    VEIGA, I
    BORRESEN, AL
    SOBRINHOSIMOES, M
    CANCER GENETICS AND CYTOGENETICS, 1994, 75 (01) : 45 - 50
  • [33] p53 alterations in porokeratosis
    Arranz-Salas, I
    Sanz-Trelles, A
    Bautista-Ojeda, D
    JOURNAL OF CUTANEOUS PATHOLOGY, 2003, 30 (07) : 455 - 458
  • [34] THE PROGNOSTIC ROLE OF ALTERATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN SUPERFICIAL AND ADVANCED-STAGE BLADDER-CANCER
    KUCZYK, MA
    BOKEMEYER, C
    SCHMOLL, HJ
    JONAS, U
    ONKOLOGIE, 1995, 18 (03): : 202 - 210
  • [35] P53 alterations in colon tumors - A comparison of SSCP/sequencing and immunohistochemistry
    Curtin, K
    Slattery, ML
    Holubkov, R
    Edwards, S
    Holden, JA
    Samowitz, WS
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2004, 12 (04): : 380 - 386
  • [37] Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb
    A W Hitchings
    M Kumar
    S Jordan
    V Nargund
    J Martin
    D M Berney
    British Journal of Cancer, 2004, 91 : 552 - 557
  • [38] Combined targeting of the p53 and pRb pathway in neuroblastoma
    Schubert, Nil
    Schild, Linda
    van Oirschot, Stijn
    Keller, Kaylee
    Alles, Lindy
    Vernooij, Lindy
    Nulle, Marloes
    Dolman, Emmy
    van den Boogaard, Marlinde
    Molenaar, Jan
    CANCER RESEARCH, 2020, 80 (14) : 69 - 69
  • [39] Gankyrin: a new oncoprotein and regulator of pRb and p53
    Dawson, Simon
    Higashitsuji, Hiroaki
    Wilkinson, Anthony J.
    Fujita, Jun
    Mayer, R. John
    TRENDS IN CELL BIOLOGY, 2006, 16 (05) : 229 - 233
  • [40] The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder
    Ibrahim, N.
    Elzagheid, A.
    El-Hashmi, H.
    Syrjanen, K.
    Alhakim, S.
    LIBYAN JOURNAL OF MEDICINE, 2009, 4 (04) : 143 - 145